Patient characteristics (n = 14)
| Characteristics . | Patients, n . |
|---|---|
| Median age (range), y | 59 (44-84) |
| Male sex, n (%) | 11 (79) |
| ECOGstatus, n (%) | |
| 0 | 2 (14) |
| 1 | 11 (79) |
| 2 | 1 (7) |
| Primary histologic diagnosis | |
| Enteropathy-associated T-cell lymphoma, type II | 1 |
| γ-δ hepatosplenic T-cell lymphoma | 1 |
| HTLV-1 associated adult T-cell leukemia/lymphoma | 1 |
| Peripheral T-cell lymphoma, not otherwise specified | 3 |
| Alk-negative anaplastic large cell lymphoma | 1 |
| MF | 2 |
| MF transformed to large cell lymphoma | 2 |
| MF/SS | 2 |
| Cutaneous γ-δ T-cell lymphoma | 1 |
| Disease stage at study entry, n (%) | |
| PTCL (n = 7) | |
| Stage IV | 7 (100) |
| CTCL (n = 7) | |
| MF, stage IB | 2 (14) |
| MF, stage IVA1 | 2 (14) |
| MF transformed to large cell lymphoma, stage IV | 2 (14) |
| Cutaneous γ-δ T-cell lymphoma, stage IV | 1 (7) |
| Refractory to most recent therapy, n (%) | 14 (100) |
| Median time from diagnosis to study entry (range), y | 4.4 (0.4-14.8) |
| Median prior lines of therapy, n (range) | 4 (1-11) |
| For MF patients (n = 6), prior systemic treatment, n (%) | |
| Histone deacetylase inhibitor | 5 (83) |
| Oral retinoid therapy | 6 (100) |
| Oral methotrexate | 4 (67) |
| Interferon | 3 (50) |
| Chemotherapy | 5 (83) |
| Total skin electron beam therapy | 4 (67) |
| Denileukin diftitox | 1 (17) |
| Alemtuzumab | 1 (17) |
| Characteristics . | Patients, n . |
|---|---|
| Median age (range), y | 59 (44-84) |
| Male sex, n (%) | 11 (79) |
| ECOGstatus, n (%) | |
| 0 | 2 (14) |
| 1 | 11 (79) |
| 2 | 1 (7) |
| Primary histologic diagnosis | |
| Enteropathy-associated T-cell lymphoma, type II | 1 |
| γ-δ hepatosplenic T-cell lymphoma | 1 |
| HTLV-1 associated adult T-cell leukemia/lymphoma | 1 |
| Peripheral T-cell lymphoma, not otherwise specified | 3 |
| Alk-negative anaplastic large cell lymphoma | 1 |
| MF | 2 |
| MF transformed to large cell lymphoma | 2 |
| MF/SS | 2 |
| Cutaneous γ-δ T-cell lymphoma | 1 |
| Disease stage at study entry, n (%) | |
| PTCL (n = 7) | |
| Stage IV | 7 (100) |
| CTCL (n = 7) | |
| MF, stage IB | 2 (14) |
| MF, stage IVA1 | 2 (14) |
| MF transformed to large cell lymphoma, stage IV | 2 (14) |
| Cutaneous γ-δ T-cell lymphoma, stage IV | 1 (7) |
| Refractory to most recent therapy, n (%) | 14 (100) |
| Median time from diagnosis to study entry (range), y | 4.4 (0.4-14.8) |
| Median prior lines of therapy, n (range) | 4 (1-11) |
| For MF patients (n = 6), prior systemic treatment, n (%) | |
| Histone deacetylase inhibitor | 5 (83) |
| Oral retinoid therapy | 6 (100) |
| Oral methotrexate | 4 (67) |
| Interferon | 3 (50) |
| Chemotherapy | 5 (83) |
| Total skin electron beam therapy | 4 (67) |
| Denileukin diftitox | 1 (17) |
| Alemtuzumab | 1 (17) |
ECOG, Eastern Cooperative Oncology Group; MF, mycosis fungoides; SS, Sezary syndrome.